^“The proapoptotic BH3-only protein BAD transduces cell death signals independently of its interaction with Bcl-2”. Cell Death Differ.9 (11): 1240–7. (2002). doi:10.1038/sj.cdd.4401097. PMID12404123.
^ abcdef“Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function”. Mol. Cell17 (3): 393–403. (February 2005). doi:10.1016/j.molcel.2004.12.030. PMID15694340.
^ ab“Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death”. Cell80 (2): 285–91. (January 1995). doi:10.1016/0092-8674(95)90411-5. PMID7834748.
^ abc“Underphosphorylated BAD interacts with diverse antiapoptotic Bcl-2 family proteins to regulate apoptosis”. Apoptosis6 (5): 319–30. (October 2001). doi:10.1023/A:1011319901057. PMID11483855.
^“Survival function of protein kinase C{iota} as a novel nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated bad kinase”. J. Biol. Chem.280 (16): 16045–52. (April 2005). doi:10.1074/jbc.M413488200. PMID15705582.
^“BAD partly reverses paclitaxel resistance in human ovarian cancer cells”. Oncogene17 (19): 2419–27. (November 1998). doi:10.1038/sj.onc.1202180. PMID9824152.
^“PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition”. Oncogene19 (46): 5291–7. (November 2000). doi:10.1038/sj.onc.1203901. PMID11077446.
^“Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members”. Cell Death Differ.6 (6): 525–32. (June 1999). doi:10.1038/sj.cdd.4400519. PMID10381646.
^ ab“Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11”. Mol. Endocrinol.11 (12): 1858–67. (November 1997). doi:10.1210/me.11.12.1858. PMID9369453.
“Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)”. Cell87 (4): 619–28. (1996). doi:10.1016/S0092-8674(00)81382-3. PMID8929531.
“BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity”. J. Biol. Chem.272 (39): 24101–4. (1997). doi:10.1074/jbc.272.39.24101. PMID9305851.
“Interference of BAD (Bcl-xL/Bcl-2-associated death promoter)-induced apoptosis in mammalian cells by 14-3-3 isoforms and P11”. Mol. Endocrinol.11 (12): 1858–67. (1997). doi:10.1210/me.11.12.1858. PMID9369453.
“Dimerization properties of human BAD. Identification of a BH-3 domain and analysis of its binding to mutant BCL-2 and BCL-XL proteins”. J. Biol. Chem.272 (49): 30866–72. (1997). doi:10.1074/jbc.272.49.30866. PMID9388232.
“The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136”. Curr. Biol.8 (13): 779–82. (1998). doi:10.1016/S0960-9822(98)70302-1. PMID9651683.
“BAD partly reverses paclitaxel resistance in human ovarian cancer cells”. Oncogene17 (19): 2419–27. (1998). doi:10.1038/sj.onc.1202180. PMID9824152.
“Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members”. Cell Death Differ.6 (6): 525–32. (1999). doi:10.1038/sj.cdd.4400519. PMID10381646.
“Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase”. J. Biol. Chem.274 (43): 31108–13. (1999). doi:10.1074/jbc.274.43.31108. PMID10521512.
“Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms”. Science286 (5443): 1358–62. (1999). doi:10.1126/science.286.5443.1358. PMID10558990.